Trial Profile

Phase 2 Study to Assess the Safety and Efficacy of Bomedemstat (IMG-7289) in Combination With Ruxolitinib in Patients With Myelofibrosis

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bomedemstat (Primary) ; Ruxolitinib (Primary)
Indications Myelofibrosis
Focus Adverse reactions

Most Recent Events

12 Dec 2023 Early Results (At the data cut-off of 30 June 2023, n=32), presented at the 65th American Society of Hematology Annual Meeting and Exposition
21 May 2023 Planned number of patients changed from 20 to 40.
21 May 2023 Planned End Date changed from 30 Oct 2025 to 31 Dec 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com